Home
News
Interviews
Companies
Videos
Markets
Subscribe
The
Latest
The Latest
News
Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds
News
Pharmather Files for FDA Orphan Drug Designation for Ketamine in Parkinson's Disease
News
Cybin and Clarmin Announce Closing of CDN$45 Million Oversubscribed Private Placement and Provide Update on RTO
News
Havn Life Sciences Announces Appointment of Dennis Staudt to the Board of Directors & Senior Management Reorganization
More Articles
FEATURED
Cybin and Clarmin Announce Closing of CDN$45 Million Oversubscribed Private Placement and Provide Update on RTO
News
Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange
News
Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds
Trending
#
Spotlight
Garyn Angel | Founder & CEO, Magical Brands
#
Spotlight
Susan Chapelle | Co-CEO, Havn Life
#
Spotlight
Matthew Johnson
#
News
Psychedelic Research Fundraising Campaign Attracts $30 Million in Donations in 6 Months, Prepares MDMA-Assisted Psychotherapy for FDA Approval
#
News
Psychedelic Drugs Market Projected to Reach $6.85 Billion by 2027
Companies
#
Havn Life
NEO
CSE
TSXV
Private Company
#
Champignon Brands
NEO
CSE
TSXV
Private Company
#
Mind Medicine (MindMed)
NEO
CSE
TSXV
Private Company
#
Mydecine Innovations Group
NEO
CSE
TSXV
Private Company
#
Novamind Ventures
NEO
CSE
TSXV
Private Company
